跳至主要内容
临床试验/CTRI/2024/05/066846
CTRI/2024/05/066846尚未招募2 期

Impact of GLUBLOC On postprandial blood gulcose and insulin levels in patients with diabetes and healthy individuals post high carb meal intake

My Pura Vida Wellness Private Limited (Puravida)1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2024年5月27日最近更新:

试验速览

阶段
2 期
状态
尚未招募
发起方
入组人数
60
试验地点
1
主要终点
1. To document the impact of

研究概览

简要总结

In the current study we aimed at understanding the anti-diabetic activity of the nutraceutical powder containing glublocâ„¢ (a proprietary blend of Morus alba L and Malus domestica peel extract) in improving the HbA1C, glucose and inulin levels in diabetic individuals. This will be added as a nutraceutical/ dieraty supplement to their current medication and evaluate the improvements in HbA1C, glucose and inulin levels at the end of 3rd month and 6th month of intervention and the assessments were compared to placebo intake

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Participant and Investigator Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Healthy subjects: 1.Aged between 18–60 years, 2.BMI between 18.5 and 22.9 kg/m2 3.Fasting blood glucose range between 3.9 and 5.5 mmol/L.
  • Diabetes Patients 1.Aged between 18–60 years, 2.BMI between 18.5 and 29.9 kg/m2 3.Fasting blood glucose ≥ 7.2 mmol/L (or) ≥ 126 mg/dl or HbA1C ≥ 6.5%.

排除标准

  • Healthy subjects: 1.Women who were pregnant or lactating 2.Any known food allergies 3.Subjects with a bleeding disorder 4.Pre-existing medical condition or taking medication known to affect glucose regulation and/or influence digestion and absorption of nutrients 5.History of diabetes mellitus (type I/II) or they used antihyperglycaemic drugs or insulin to treat diabetes or related conditions 6.Used steroids, protease inhibitors or antipsychotic medicines as these drugs are known to impact glucose metabolism and body fat distribution.
  • Diabetes Patients: 1.food allergies.
  • 2.Used steroids, protease inhibitors or antipsychotic medicines as these drugs are known to impact glucose metabolism and body fat distribution.
  • 3.Subjects with the history of uncontrolled hypertension and/or hyperthyroidism.
  • 4.History of alcoholism 5.Subjects with psychiatric or neurological disability or mental health disorder 6.Subjects with serious health conditions such as cardiac disease, renal dysfunction, and cancers.
  • 7.Female subjects who are pregnant or had planned for pregnancy in the following months or were breast-feeding.
  • 8.Subjects who refuse to sign informed consent.
  • 9.According to the investigator’s opinion, participants who are deemed unable to comply with the test requirements or otherwise deemed unsuitable.

结局指标

主要结局

1. To document the impact of

时间窗: Baseline samples before intervention, end of the 3rd Month and end of the six month

GLUBLOC supplementation in patients with diabetes and healthy

时间窗: Baseline samples before intervention, end of the 3rd Month and end of the six month

individuals

时间窗: Baseline samples before intervention, end of the 3rd Month and end of the six month

次要结局

  • To document adverse effect if any on study product(Baseline samples before intervention, end of the 3rd Month and end of the six month)

研究者

发起方
My Pura Vida Wellness Private Limited (Puravida)
申办方类型
Other [online health and wellness company]
责任方
Principal Investigator
主要研究者

Balamurugan Ramadass

All India Institute of Medical Sciences

研究点 (1)

Loading locations...

相似试验